ProMab Biotechnologies, Inc.
Promab has over 15 years monoclonal antibody development expertise, successfully completing over 3000 monoclonal antibody projects, developed more than 1500 commercial monoclonal antibodies, targeting tumor antigens, intracellular proteins, and cancer stem cell markers. Promab Biotechnologies developed' new custom Chimeric Antigen Receptor-T Cell service and product development programs validated in vitro and in vivo for pre-clinical and future clinical applications. Promab provides a unique approach for the immunotherapy field, pursuing partnerships for developing customized products.